Episodes (Page 18)
✨
US FDA leadership departures impact facility inspections and drug promotion.
✨
Ochre Bio's novel approach to RNA therapies for liver disease.
Quin Wills
✨
Trump's drug pricing order and J&J's US manufacturing views.
✨
Consumer health brands are key to successful self-care businesses.
Michelle Riddalls
✨
Trump's tariff volatility and Q1 earnings uncertainties.
✨
US potential tariffs on imported drugs may face delays.
✨
Pharma dodges tariffs; FDA's Marks departs, rattling the industry.
✨
PAGB aims to influence stakeholders and navigate UK regulatory complexity.
Michelle Riddalls
✨
US FDA's April 1 reduction-in-force impacts 3,500 employees.
✨
OSE Immunotherapeutics discusses lusvertikimab's IL-7 data.
Nicolas Poirier
✨
Intuitive CEO discusses da Vinci 5 robot and surgical robotics future.
Brian Bossetta
Elizabeth Orr
Gary Guthart
Shubham Singh
✨
Merck licenses Hengrui's lipid lowerer; Novo acquires obesity drug.
✨
iOnctura CEO discusses innovative cancer therapies.
Catherine Pickering
✨
Impact of 3,500 HHS layoffs on the US FDA.
✨
Heranova CMO advocates for endometriosis awareness: 'Pain is not normal'.
Farideh Bischoff
✨
AESGP Annual Meeting in Warsaw focuses on European self-care.
Jurate Svarcaite
✨
Pfizer leads pharma leaderboard; AstraZeneca invests in cell therapy.
✨
FDA productivity complaints arise following recent changes.
✨
Roche secures a major obesity drug deal.
✨
FDA workforce reductions via early retirement and buyouts.